SITE008-0386

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-06-11

AEs

Serious

Dropout signal

–

Adverse events

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-06-27 (study day 11); relationship: not assessed

moderate assessed

Grade 2 Peripheral neuropathy — outcome: UNKNOWN; onset 2023-07-08 (study day 22); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-02 (study day 47); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-12 (study day 57); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-11 (study day 87); relationship: N

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-11 (study day 87); relationship: N

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 90); relationship: not assessed

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-30 (study day 106); relationship: Y

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-05 (study day 111); relationship: N

Data queries

No data queries.